News and updates
Follow Serendo Therapeutics as we advance our science, build partnerships, and mark key company milestones.
Serendo Selected to Pitch at BIO-Europe Spring 2026
March 2026
Serendo Therapeutics has been selected to pitch at BIO-Europe Spring 2026, one of the key international partnering events in the life science industry. The selection highlights Serendo’s growing visibility within biotech and reflects the increasing interest in the company’s approach to developing innovative therapies in autoimmune disease. Participating in BIO-Europe Spring provides Serendo with a valuable opportunity to present its vision, showcase its scientific platform, and engage with potential partners, investors and industry leaders from across Europe and beyond.
Strengthening the Team: Lars Smedegaard Andersen Joins Serendo
February 2026
Serendo Therapeutics is pleased to welcome Lars Smedegaard Andersen to the company. Lars brings extensive experience from the life science sector and adds valuable strategic, commercial and business development expertise as Serendo continues to grow. His addition further strengthens the company’s leadership team at an important stage in its development and supports Serendo’s ambition to build strong partnerships and create long-term value around its scientific platform and pipeline.
Vinnova Grant Supports Serendo’s Next Phase of Growth
November 2025
Serendo Therapeutics has received a grant from the Swedish innovation agency Vinnova through the Innovative Company call. This funding supports the company’s continued development and strengthens the foundation for future growth. The grant represents an important recognition of Serendo’s innovation potential and helps accelerate the company’s efforts to translate its scientific discoveries into therapies with the potential to make a real difference for patients. It also provides further momentum as Serendo continues to build its capabilities and move forward in its development journey.
Serendo Selected to Pitch at Nordic Life Science Days
October 2025
Serendo Therapeutics has been selected to pitch at Nordic Life Science Days, one of the leading life science partnering events in the Nordics. This opportunity gives Serendo a strong platform to present its vision and connect with key stakeholders in the sector. Being selected to pitch at such a recognized event highlights the relevance of Serendo’s scientific and business proposition and creates valuable opportunities for dialogue with potential investors, collaborators and industry partners.
HALRIC Pilot Project Awarded in Collaboration with Technical University of Denmark
September 2025
Serendo Therapeutics has been awarded a HALRIC EU pilot project together with the Technical University of Denmark. The project marks an important step in supporting Serendo’s scientific development through collaboration and innovation. Through this initiative, Serendo gains the opportunity to work in a strong research environment and further advance key parts of its development activities. The award also underlines external confidence in the company’s scientific direction and the relevance of its work in addressing important unmet needs in autoimmune disease.
Hear the Story Behind Serendo in a New Podcast Feature
27 March 2025
Serendo Therapeutics has been featured in a podcast episode sharing more about the company’s background, vision and journey. The episode offers additional insight into the people and ideas behind Serendo and provides listeners with a broader understanding of the company’s scientific focus and entrepreneurial ambition. It is a valuable opportunity to hear more about the thinking behind Serendo and the motivation for building a company dedicated to innovative therapeutic development.
Serendo Therapeutics Launches with a Vision for Innovation
February 2025
Serendo Therapeutics has launched with a clear ambition to advance innovative therapies and build a company rooted in strong science and meaningful impact for patients. The launch marks the beginning of Serendo’s journey and public introduction, establishing the company’s presence and setting out its long-term vision. From the outset, Serendo positions itself around a strong scientific foundation and a commitment to translating research into therapeutic innovation with the potential to address significant unmet medical needs.